Member Info for HotblackDesiato

Evening SOG - whilst we've both mentioned AZD1775 previously, I can't find a link between AstraZeneca (or Merck) and any privately owned US biopharma so I don't think we'll be seeing a SAR/AZ deal any time soon (more's the pity).

https://delta.larvol.com/Products/?ProductId=326ab820-1f70-446a-a97a-a9e6d947e352&Index=0

Perhaps the BoD are hoping that RF have gone to the wall by Aug 2025. It'd be a fitting end.

You'd certainly hope Clive Birch knows precisely where we stand re who owes what and when. He should now be advising T&J whether or not to utilise the excess WRAP monies to pay them off or press on with 1802.

As you'll know, Sierra applied for a number of 737-related patents but the IP was to be handed over when they returned 737. The list below was collated from the Google Patents site. It shows the patent & current assignee - make of it what you will:

Publication number: 20230150994 - Methods for synthesis of chk1 inhibitors - Sierra Oncology Inc

Publication number: 20200397796 - Methods of treatment of cancer comprising chk1 inhibitors - Crt Pioneer Fund Lp

Publication number: 20220184091 - Methods of Treating Cancer with Chk1 Inhibitors - MD Anderson Cancer Center/Sierra Oncology Inc

Publication number: 20210077499 - Chk1 (sra737)/parpi combination methods of inhibiting tumor growth - Crt Pioneer Fund Lp

Publication number: 11596637 - CHK1 (SRA737)/PARPi combination methods of inhibiting tumor growth - Crt Pioneer Fund Lp

Publication number: 20220226338 - Methods of Treating Cancer Using CHK1 Inhibitors - Crt Pioneer Fund Lp

Hi SOG - the recent RNS notes, "The goal of the proposed Phase 2a trial would be to recruit up to 24 psoriasis patients..."

Regards.

When I got SC clearance I was amazed I could remember the answers to some of the questions! I feel sorry for whoever had to look through my internet search history!

Which company? If you mean RiverFort then probably.

My apologies to other posters, my interaction with the little prince will end here.

Puma - That’s very simplistic. Based on your logic, you expect the 9.5m shares to be sold off at a loss?

On a different topic, do you have the word 'slave' written on your cheek as a tribute to the short purple one?

Thanks for the reply, Potnak. That would be some hike from 10.5p today to 20/30p on Monday if it happens.

Cobalt - the 9.5m shares cost 10p each. Would you look to sell them to punters for more or less than 10p?!?

I'm just wondering what might happen on Monday when people start loading up their ISAs. If the 9.5m placing shares are newly available from Friday, will we see a large spread next week if MMs hike the ask price but keep the bid low e.g. 13p+ to buy but 10p to sell?

Would appreciate any thoughts on this.

Hi Damion, a poster here beat Edison to the punch on that point too. Someone posted at the end of Dec that the Nucleus Network were still recruiting and posted again when the advert no longer appeared on their site.

I can't think who it was.........

;-)

Meh, for £60k a year it looks like Edison just collated what a few posters here give out for free.

The Equity Raise RNS states that the new shares will be admitted, "...by 8.00 a.m. on 5 April 2024 (or such later time as the Company and Hybridan LLP may agree, being not later than 8.30 a.m. on 30 April 2024)."

So it looks like the BoD could still have nearly the whole month to decide on what to do with the proceeds before they have to issue an RNS saying if they're keeping the full £2.2m or reducing the number of placing shares (circa 9.5m) in order to go with the original £1.5m that they intended.

What I don't want to see is them taking the full £2.2m and quietly increasing their salaries back to pre-raise levels.

Hi Laz - not sure I agree with your 'once bitten twice shy' approach (though I do understand it). The world changes and there may be many reasons why it could make sense to approach the MHRA again. If they've sorted their internal processes out and made it easier for compounds with no MTD to progress, ignoring this option might be akin to cutting off your nose to spite your face. JR may grind his teeth at the thought of dealing with the MHRA again but now we'll have P1a data that they can't dispute.

Just to add, if the BoD just need £1.5 then I don't see why they can't reduce the 9.5m placing shares to around 2m in order to reduce dilution.

No doubt they are huddled in their shed wondering how to use the funds - take the full £2.2m now and full steam ahead or settle on £1.5m and see what the future holds re partners/licencing.

Morning SOG - The way I read it, they've managed to raise:

A) 9,550,000 shares via a placing = £955,000

B) 2,255,000 shares via HNWs = £225,500

C) 3,000,000 shares via WRAP = £300,000

Total: 14,805,000 shares for £1,480,500 raised (ignoring advisor fees/shares & shares in lieu of historic director salaries)

However the WRAP was increased so:

D) 11,189,733 shares via the WRAP = £1,118,973

(this includes 195,000 shares via Director WRAP = £19,500)

Therefore I think the total raised is A+B+D = £2,299,473

Surely enough to get P2a on the road and hopefully get the 1802 translational studies completed.

Question is, will we see anyone submit a TR1?

Indeed, Ben. I bought another £4500 on the open market (needless to say mid-morning when the sp was near the top - I never learn!)

Just think how much more it could've been if Halifax (and others) had taken part. I may have to write a stiff letter to them.

Hi Laz - thanks for the reply. It would be good if we could pay off RF and cancel any warrants but I suppose we're better off using the funds to progress 1801/2.

The next question is will the MMs play silly buggers on Monday by significantly raising the sp to catch out early bird S&S ISA buyers before dropping it again?

Could RF forward sell their shares?

Good to hear it all went well, Warthog.

Since you're now part titanium you might enjoy this video whilst you recuperate - https://www.youtube.com/watch?v=hFJMs15sVSY